본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel.

Ahn, Jeong Cheon    (Departments of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea   ); Song, Woo Hyuk    (Departments of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea   ); Kwon, Jung Ah    (Laboratory Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea   ); Park, Chang Gyu    (Departments of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea   ); Seo, Hong Seok    (Departments of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea   ); Oh, Dong Joo    (Departments of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea   ); Rho, Young Moo    (Departments of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Seoul, Korea  );
  • 초록

    Background : A recent study has shown that triple anti-platelet therapy (cilostazol+clopidogrel+aspirin) resulted in a significantly lower restenosis rate after coronary stenting than did conventional therapy (clopidogrel+aspirin). However, the anti-platelet effects of cilostazol, when combined with clopidogrel and aspirin, have not been evaluated. Methods : Low dose cilostazol (50 mg/BID) was given to 47 patients who had already been taking clopidogrel (75 mg/day) and aspirin (100 mg/day) for more than 1 month subsequent to coronary stenting due to AMI and unstable angina. Markers of platelet activation, P-selectin and activated GPIIb/IIIa on platelets, were measured at baseline and 2 weeks after cilostazol treatment. We empirically divided patients into tertiles (low, n=16; moderate, n=14; high group, n=17), according to the baseline P-selectin expression. We then performed a comparative assessment of the anti-platelet effects of cilostazol at baseline and after 2 weeks of cilosatzol administration. Results : P-selectin was significantly decreased after 2 weeks of cilostazol treatment in total patients (n=47, 3.2±2.4% to 2.0±1.9%, p = 0.03). This inhibition of P-selectin expression was mainly achieved in the moderate and high P-selectin groups (low group; 1.4±0.5 to 1.9±1.3%, p >0.05, moderate group; 2.5±0.3 to 1.3±0.3%, p p p Conclusion : Our data demonstrated that cilostazol treatment in addition to conventional anti-platelet therapy provides more effective suppression of platelet P-selectin expression in patients with relatively high platelet activity.


  • 주제어

    Antiplatelet therapy .   Coronary stent.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기